Plain-English translation of NCT06843629 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a new imaging approach using PET scans that target a specific protein called mesothelin, which appears in high amounts on certain cancer cells. The study aims to see if this imaging method can better detect and diagnose ovarian cancer, lung adenocarcinoma, and pancreatic cancer. Researchers hope this new scan will help catch these cancers earlier, when they may be easier to treat.
Many cancers are not caught until they're advanced because they don't cause obvious symptoms early on. This trial is exploring a new way to create better images of these hard-to-detect cancers by targeting a protein that shows up on cancer cells, potentially helping doctors diagnose these diseases sooner and improve patient outcomes.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will undergo specialized imaging scans (PET/MR or PET/CT) designed to detect cancer using the new mesothelin-targeting method. You'll need to meet with the research team for screening and evaluation, complete the imaging scans, and possibly have blood tests and other assessments. The research team will provide specific details about visit schedules and what to expect during each scan.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China